BioDelivery Sciences announced the launch of Bunavail (buprenorphine and naloxone) buccal film. Bunavail is the first buccal formulation of buprenorphine and naloxone.

Bunavail is a Schedule III controlled substance indicated as maintenance treatment of opioid dependence and as part of a complete treatment plan to include counseling and psychosocial support.

Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is a potent antagonist at mu-opioid receptors and produces opioid withdrawal signs and symptoms, if administered parenterally, in individuals physically dependent on full opioid agonists.

RELATED: New Treatment for Opioid Dependence Approved

Bunavail incorporates BioErodible MucoAdhesive (BEMA), the company’s patented, thin film drug delivery technology. This enables efficient and convenient delivery of buprenorphine without some of the administration difficulties associated with sublingual dosage forms that are currently on the market.

Bunavail is available as 2.1mg/0.3mg, 4.2mg/0.7mg, and 6.3mg/1mg strengths in 30-count boxes.

For more information call (800) 469-0261 or visit